HIF1A and pulmonary fibrosis: Further, the promotion of FAO, inhibition of glycolysis and HIF‐1α reduce ECM production and promote ECM degradation, ultimately impeding the progression of fibrosis and providing therapeutic relief for established pulmonary fibrosis in vivo.